Rare genetic diseases are challenging for patients and their families—made all the more overwhelming because symptoms tend to ...

Scientists have created a near-copy of the long-extinct dire wolf. Using advanced CRISPR gene editing tech, it now looks ...

It is the first time this mechanism has been found in eukaryotes, such as animals. Unlike CRISPR proteins, Fanzor enzymes are encoded in the eukaryotic genome within transposable elements and the team ...

Nature has developed numerous remarkable strategies for reproduction throughout evolutionary history. While most animals reproduce sexually, combining genetic material from two parents, some species ...

Estimates for CRISPR’s 2025 loss per share have widened from $5.06 to $5.54 in the past 60 days. During the same timeframe, loss per share estimates for 2026 have increased from $3.76 to $4.30.

CRISPR-Cas systems are now widely used for genome editing and transcriptional regulation in diverse organisms. The compact and portable nature of class 2 single effector nucleases, such as Cas9 or ...

Keywords: melon, in planta genome editing, particle bombardment, CRISPR/Cas9 RNP, DNA-free, ethylene Citation: Sasaki K, Urano K, Mimida N, Nonaka S, Ezura H and Imai R (2025) A long shelf-life melon ...

Evolution, the cornerstone of biology, explains the adaptation and survival strategies of life on Earth. Some animals, however, seem to challenge evolutionary norms with their unique adaptations and ...

Victoria Gray, the first person cured of sickle cell using CRISPR gene editing therapies, spoke in Fargo about her journey and the need to lower the $2M treatment cost.

Accurate and sensitive detection of single nucleotide polymorphism (SNP) holds significant clinical implications, especially in the field of cancer diagnosis. Leveraging its high accuracy and ...

The patents involved, U.S. Patent Nos. 10,337,001 and 10,900,034, owned by Agilent Technologies, claimed chemically modified synthetic CRISPR guide RNAs featuring modifications like 2?-O-methyl ...

In the original case, ruling dated May 17, 2023, the Patent Trial and Appeal Board (PTAB) ruled in favor of Synthego's petitions seeking to invalidate Agilent's US Patents Nos. 10,337,001 (the '001 ...